吡非尼酮
外觀
![]() | |
臨床資料 | |
---|---|
商品名 | Esbriet, Pirespa, Etuary |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615008 |
核准狀況 |
|
懷孕分級 | |
給藥途徑 | By mouth |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
血漿蛋白結合率 | 50–58%[7] |
藥物代謝 | Liver (70–80% CYP1A2-mediated; minor contributions from CYP2C9, CYP2C19, CYP2D6 and CYP2E1)[7] |
生物半衰期 | 2.4 hours[7] |
排泄途徑 | Urine (80%)[7] |
識別資訊 | |
| |
CAS號 | 53179-13-8 |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.150.129 |
化學資訊 | |
化學式 | C12H11NO |
摩爾質量 | 185.23 g·mol−1 |
3D模型(JSmol) | |
水溶性 | 10mg/mL at 60 °C |
| |
|
吡非尼酮(英語:Pirfenidone,商品名有 Pirespa 等)是一種含氮有機化合物,分子式C
12H
11NO,用於治療特發性肺纖維化,其作用機制是通過下調生長因子以及I型和II型前膠原的表達來減輕肺纖維化[8][6]。
參考文獻
[編輯]- ^ 1.0 1.1 Esbriet® (pirfenidone) Film coated tablets. Roche Products Pty Limited. medsinfo.com.au. [8 January 2023]. (原始內容存檔於8 January 2023).
- ^ Esbriet® (pirfenidone) Capsules. Roche Products Pty Limited. medsinfo.com.au. [8 January 2023]. (原始內容存檔於8 January 2023).
- ^ Prescription medicines: registration of new chemical entities in Australia, 2016. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. (原始內容存檔於10 April 2023).
- ^ Esbriet Product information. Health Canada. 25 April 2012 [8 January 2023]. (原始內容存檔於8 January 2023).
- ^ Esbriet- pirfenidone capsule Esbriet- pirfenidone tablet, coated. DailyMed. 14 December 2022 [8 January 2023]. (原始內容存檔於8 January 2023).
- ^ 6.0 6.1 Esbriet EPAR. European Medicines Agency. 17 September 2018 [19 June 2020]. (原始內容存檔於24 November 2020).
- ^ 7.0 7.1 7.2 7.3 Esbriet 267 mg hard capsules. electronic Medicines Compendium. Intermune UK & I Ltd. 3 January 2014 [6 March 2014]. (原始內容存檔於12 October 2013).
- ^ InterMune: Pirfenidone. InterMune. [17 December 2015]. (原始內容存檔於21 October 2020).